カテゴリー： Market Monitor Global, 世界, 医療/バイオ

卵巣がん治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Ovarian Cancer Drugs Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5865）

◆商品コード：MMG23JU5865
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月（※2025年版があります。お問い合わせください。）
◆ページ数：74
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Ovarian Cancer Drugs Market 調査レポートは次の情報を含め、グローバルにおけるの卵巣がん治療薬市場規模と予測を収録しています。・世界の卵巣がん治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の卵巣がん治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の卵巣がん治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「手術」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

卵巣がん治療薬のグローバル主要企業は、Bristol Myers Squibb、 Eli Lilly、 GlaxoSmithKline、 Janssen Pharmaceuticals、 Novogen、 Genentech、 Aetera Zenteris、 Boehringer Ingelheim、 Rocheなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、卵巣がん治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の卵巣がん治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の卵巣がん治療薬市場：タイプ別市場シェア、2022年
・手術、化学療法、放射線療法、生物学的療法

世界の卵巣がん治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の卵巣がん治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の卵巣がん治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の卵巣がん治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における卵巣がん治療薬のグローバル売上、2018年-2023年
・主要企業における卵巣がん治療薬のグローバル売上シェア、2022年
・主要企業における卵巣がん治療薬のグローバル販売量、2018年-2023年
・主要企業における卵巣がん治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Bristol Myers Squibb、 Eli Lilly、 GlaxoSmithKline、 Janssen Pharmaceuticals、 Novogen、 Genentech、 Aetera Zenteris、 Boehringer Ingelheim、 Roche

*************************************************************

・調査・分析レポートの概要
卵巣がん治療薬市場の定義
市場セグメント
世界の卵巣がん治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の卵巣がん治療薬市場規模
世界の卵巣がん治療薬市場規模：2022年 VS 2029年
世界の卵巣がん治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの卵巣がん治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の卵巣がん治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：手術、化学療法、放射線療法、生物学的療法
卵巣がん治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
卵巣がん治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別卵巣がん治療薬市場規模 2022年と2029年
地域別卵巣がん治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Bristol Myers Squibb、 Eli Lilly、 GlaxoSmithKline、 Janssen Pharmaceuticals、 Novogen、 Genentech、 Aetera Zenteris、 Boehringer Ingelheim、 Roche
...

Ovarian cancer is regarded as one of the most common types of cancer among women. It accounts for more deaths than any other cancer of the female reproductive system, while it ranks 5th in overall women deaths due to cancer. This type of cancer is rarely diagnosed at an early stage, making treatment at an advanced stage difficult.
This report aims to provide a comprehensive presentation of the global market for Ovarian Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ovarian Cancer Drugs. This report contains market size and forecasts of Ovarian Cancer Drugs in global, including the following market information:
Global Ovarian Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Ovarian Cancer Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Ovarian Cancer Drugs companies in 2022 (%)
The global Ovarian Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Surgery Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Ovarian Cancer Drugs include Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novogen, Genentech, Aetera Zenteris, Boehringer Ingelheim and Roche, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ovarian Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ovarian Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ovarian Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Surgery
Chemotherapy
Radiation
Biological Therapy
Global Ovarian Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ovarian Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinics
Others
Global Ovarian Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ovarian Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ovarian Cancer Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Ovarian Cancer Drugs revenues share in global market, 2022 (%)
Key companies Ovarian Cancer Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Ovarian Cancer Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol Myers Squibb
Eli Lilly
GlaxoSmithKline
Janssen Pharmaceuticals
Novogen
Genentech
Aetera Zenteris
Boehringer Ingelheim
Roche
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ovarian Cancer Drugs, market overview.
Chapter 2: Global Ovarian Cancer Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Ovarian Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ovarian Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ovarian Cancer Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Ovarian Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Ovarian Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ovarian Cancer Drugs Overall Market Size
2.1 Global Ovarian Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Ovarian Cancer Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Ovarian Cancer Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Ovarian Cancer Drugs Players in Global Market
3.2 Top Global Ovarian Cancer Drugs Companies Ranked by Revenue
3.3 Global Ovarian Cancer Drugs Revenue by Companies
3.4 Global Ovarian Cancer Drugs Sales by Companies
3.5 Global Ovarian Cancer Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Ovarian Cancer Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Ovarian Cancer Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Ovarian Cancer Drugs Players in Global Market
3.8.1 List of Global Tier 1 Ovarian Cancer Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Ovarian Cancer Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Ovarian Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Surgery
4.1.3 Chemotherapy
4.1.4 Radiation
4.1.5 Biological Therapy
4.2 By Type – Global Ovarian Cancer Drugs Revenue & Forecasts
4.2.1 By Type – Global Ovarian Cancer Drugs Revenue, 2018-2023
4.2.2 By Type – Global Ovarian Cancer Drugs Revenue, 2024-2029
4.2.3 By Type – Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Ovarian Cancer Drugs Sales & Forecasts
4.3.1 By Type – Global Ovarian Cancer Drugs Sales, 2018-2023
4.3.2 By Type – Global Ovarian Cancer Drugs Sales, 2024-2029
4.3.3 By Type – Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Ovarian Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Ovarian Cancer Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinics
5.1.4 Others
5.2 By Application – Global Ovarian Cancer Drugs Revenue & Forecasts
5.2.1 By Application – Global Ovarian Cancer Drugs Revenue, 2018-2023
5.2.2 By Application – Global Ovarian Cancer Drugs Revenue, 2024-2029
5.2.3 By Application – Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Ovarian Cancer Drugs Sales & Forecasts
5.3.1 By Application – Global Ovarian Cancer Drugs Sales, 2018-2023
5.3.2 By Application – Global Ovarian Cancer Drugs Sales, 2024-2029
5.3.3 By Application – Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Ovarian Cancer Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Ovarian Cancer Drugs Market Size, 2022 & 2029
6.2 By Region – Global Ovarian Cancer Drugs Revenue & Forecasts
6.2.1 By Region – Global Ovarian Cancer Drugs Revenue, 2018-2023
6.2.2 By Region – Global Ovarian Cancer Drugs Revenue, 2024-2029
6.2.3 By Region – Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Ovarian Cancer Drugs Sales & Forecasts
6.3.1 By Region – Global Ovarian Cancer Drugs Sales, 2018-2023
6.3.2 By Region – Global Ovarian Cancer Drugs Sales, 2024-2029
6.3.3 By Region – Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Ovarian Cancer Drugs Revenue, 2018-2029
6.4.2 By Country – North America Ovarian Cancer Drugs Sales, 2018-2029
6.4.3 US Ovarian Cancer Drugs Market Size, 2018-2029
6.4.4 Canada Ovarian Cancer Drugs Market Size, 2018-2029
6.4.5 Mexico Ovarian Cancer Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Ovarian Cancer Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Ovarian Cancer Drugs Sales, 2018-2029
6.5.3 Germany Ovarian Cancer Drugs Market Size, 2018-2029
6.5.4 France Ovarian Cancer Drugs Market Size, 2018-2029
6.5.5 U.K. Ovarian Cancer Drugs Market Size, 2018-2029
6.5.6 Italy Ovarian Cancer Drugs Market Size, 2018-2029
6.5.7 Russia Ovarian Cancer Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Ovarian Cancer Drugs Market Size, 2018-2029
6.5.9 Benelux Ovarian Cancer Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Ovarian Cancer Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Ovarian Cancer Drugs Sales, 2018-2029
6.6.3 China Ovarian Cancer Drugs Market Size, 2018-2029
6.6.4 Japan Ovarian Cancer Drugs Market Size, 2018-2029
6.6.5 South Korea Ovarian Cancer Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Ovarian Cancer Drugs Market Size, 2018-2029
6.6.7 India Ovarian Cancer Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Ovarian Cancer Drugs Revenue, 2018-2029
6.7.2 By Country – South America Ovarian Cancer Drugs Sales, 2018-2029
6.7.3 Brazil Ovarian Cancer Drugs Market Size, 2018-2029
6.7.4 Argentina Ovarian Cancer Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Ovarian Cancer Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Ovarian Cancer Drugs Sales, 2018-2029
6.8.3 Turkey Ovarian Cancer Drugs Market Size, 2018-2029
6.8.4 Israel Ovarian Cancer Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Ovarian Cancer Drugs Market Size, 2018-2029
6.8.6 UAE Ovarian Cancer Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Bristol Myers Squibb
7.1.1 Bristol Myers Squibb Company Summary
7.1.2 Bristol Myers Squibb Business Overview
7.1.3 Bristol Myers Squibb Ovarian Cancer Drugs Major Product Offerings
7.1.4 Bristol Myers Squibb Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Bristol Myers Squibb Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Ovarian Cancer Drugs Major Product Offerings
7.2.4 Eli Lilly Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Company Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Ovarian Cancer Drugs Major Product Offerings
7.3.4 GlaxoSmithKline Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.3.5 GlaxoSmithKline Key News & Latest Developments
7.4 Janssen Pharmaceuticals
7.4.1 Janssen Pharmaceuticals Company Summary
7.4.2 Janssen Pharmaceuticals Business Overview
7.4.3 Janssen Pharmaceuticals Ovarian Cancer Drugs Major Product Offerings
7.4.4 Janssen Pharmaceuticals Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Janssen Pharmaceuticals Key News & Latest Developments
7.5 Novogen
7.5.1 Novogen Company Summary
7.5.2 Novogen Business Overview
7.5.3 Novogen Ovarian Cancer Drugs Major Product Offerings
7.5.4 Novogen Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Novogen Key News & Latest Developments
7.6 Genentech
7.6.1 Genentech Company Summary
7.6.2 Genentech Business Overview
7.6.3 Genentech Ovarian Cancer Drugs Major Product Offerings
7.6.4 Genentech Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Genentech Key News & Latest Developments
7.7 Aetera Zenteris
7.7.1 Aetera Zenteris Company Summary
7.7.2 Aetera Zenteris Business Overview
7.7.3 Aetera Zenteris Ovarian Cancer Drugs Major Product Offerings
7.7.4 Aetera Zenteris Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Aetera Zenteris Key News & Latest Developments
7.8 Boehringer Ingelheim
7.8.1 Boehringer Ingelheim Company Summary
7.8.2 Boehringer Ingelheim Business Overview
7.8.3 Boehringer Ingelheim Ovarian Cancer Drugs Major Product Offerings
7.8.4 Boehringer Ingelheim Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Boehringer Ingelheim Key News & Latest Developments
7.9 Roche
7.9.1 Roche Company Summary
7.9.2 Roche Business Overview
7.9.3 Roche Ovarian Cancer Drugs Major Product Offerings
7.9.4 Roche Ovarian Cancer Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Roche Key News & Latest Developments
8 Global Ovarian Cancer Drugs Production Capacity, Analysis
8.1 Global Ovarian Cancer Drugs Production Capacity, 2018-2029
8.2 Ovarian Cancer Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Ovarian Cancer Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Ovarian Cancer Drugs Supply Chain Analysis
10.1 Ovarian Cancer Drugs Industry Value Chain
10.2 Ovarian Cancer Drugs Upstream Market
10.3 Ovarian Cancer Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Ovarian Cancer Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Ovarian Cancer Drugs in Global Market
Table 2. Top Ovarian Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Ovarian Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Ovarian Cancer Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Ovarian Cancer Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Ovarian Cancer Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Ovarian Cancer Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Ovarian Cancer Drugs Product Type
Table 9. List of Global Tier 1 Ovarian Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Ovarian Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Ovarian Cancer Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Ovarian Cancer Drugs Sales (K Units), 2024-2029
Table 16. By Application – Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Ovarian Cancer Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Ovarian Cancer Drugs Sales (K Units), 2024-2029
Table 21. By Region – Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Ovarian Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Ovarian Cancer Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Ovarian Cancer Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Ovarian Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Ovarian Cancer Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Ovarian Cancer Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Ovarian Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Ovarian Cancer Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Ovarian Cancer Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Ovarian Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Ovarian Cancer Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Ovarian Cancer Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Ovarian Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Ovarian Cancer Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Ovarian Cancer Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Ovarian Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Ovarian Cancer Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Ovarian Cancer Drugs Sales, (K Units), 2024-2029
Table 46. Bristol Myers Squibb Company Summary
Table 47. Bristol Myers Squibb Ovarian Cancer Drugs Product Offerings
Table 48. Bristol Myers Squibb Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Bristol Myers Squibb Key News & Latest Developments
Table 50. Eli Lilly Company Summary
Table 51. Eli Lilly Ovarian Cancer Drugs Product Offerings
Table 52. Eli Lilly Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Eli Lilly Key News & Latest Developments
Table 54. GlaxoSmithKline Company Summary
Table 55. GlaxoSmithKline Ovarian Cancer Drugs Product Offerings
Table 56. GlaxoSmithKline Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. GlaxoSmithKline Key News & Latest Developments
Table 58. Janssen Pharmaceuticals Company Summary
Table 59. Janssen Pharmaceuticals Ovarian Cancer Drugs Product Offerings
Table 60. Janssen Pharmaceuticals Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Janssen Pharmaceuticals Key News & Latest Developments
Table 62. Novogen Company Summary
Table 63. Novogen Ovarian Cancer Drugs Product Offerings
Table 64. Novogen Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Novogen Key News & Latest Developments
Table 66. Genentech Company Summary
Table 67. Genentech Ovarian Cancer Drugs Product Offerings
Table 68. Genentech Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Genentech Key News & Latest Developments
Table 70. Aetera Zenteris Company Summary
Table 71. Aetera Zenteris Ovarian Cancer Drugs Product Offerings
Table 72. Aetera Zenteris Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Aetera Zenteris Key News & Latest Developments
Table 74. Boehringer Ingelheim Company Summary
Table 75. Boehringer Ingelheim Ovarian Cancer Drugs Product Offerings
Table 76. Boehringer Ingelheim Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Boehringer Ingelheim Key News & Latest Developments
Table 78. Roche Company Summary
Table 79. Roche Ovarian Cancer Drugs Product Offerings
Table 80. Roche Ovarian Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Roche Key News & Latest Developments
Table 82. Ovarian Cancer Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 83. Global Ovarian Cancer Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 84. Global Ovarian Cancer Drugs Production by Region, 2018-2023 (K Units)
Table 85. Global Ovarian Cancer Drugs Production by Region, 2024-2029 (K Units)
Table 86. Ovarian Cancer Drugs Market Opportunities & Trends in Global Market
Table 87. Ovarian Cancer Drugs Market Drivers in Global Market
Table 88. Ovarian Cancer Drugs Market Restraints in Global Market
Table 89. Ovarian Cancer Drugs Raw Materials
Table 90. Ovarian Cancer Drugs Raw Materials Suppliers in Global Market
Table 91. Typical Ovarian Cancer Drugs Downstream
Table 92. Ovarian Cancer Drugs Downstream Clients in Global Market
Table 93. Ovarian Cancer Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Ovarian Cancer Drugs Segment by Type in 2022
Figure 2. Ovarian Cancer Drugs Segment by Application in 2022
Figure 3. Global Ovarian Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Ovarian Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Ovarian Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Ovarian Cancer Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Ovarian Cancer Drugs Revenue in 2022
Figure 9. By Type - Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Ovarian Cancer Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Ovarian Cancer Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Ovarian Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Ovarian Cancer Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 23. US Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 28. Germany Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 37. China Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Ovarian Cancer Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Ovarian Cancer Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Ovarian Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Ovarian Cancer Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Ovarian Cancer Drugs by Region, 2022 VS 2029
Figure 54. Ovarian Cancer Drugs Industry Value Chain
Figure 55. Marketing Channels

※参考情報

卵巣がんは、女性の生殖系における主要な悪性腫瘍の一つであり、その発症率と死亡率の高さから、早期発見と効果的な治療が重要とされています。卵巣がん治療薬は、病気の進行を抑制し、患者の生存率を向上させるために開発された医薬品の総称です。これらの治療薬は、化学療法、ホルモン療法、標的療法、免疫療法といった異なるアプローチを用いて、腫瘍のサイズを減少させたり、再発を防止したりする役割を果たします。

化学療法は、卵巣がんにおいて最も一般的に行われる治療方法です。この治療は、がん細胞の成長や分裂を阻害する薬剤を使用し、全身に効果を及ぼします。主な薬剤には、パクリタキセルやカルボプラチンが含まれています。これらは、卵巣がんの治療において標準的な治療法とされており、特に手術後の補助療法として用いられています。化学療法は、がん細胞の増殖を効果的に抑えますが、正常細胞にも影響を与えるため、副作用が伴うことがあります。

ホルモン療法は、卵巣がんの中でも特にホルモン受容体陽性の腫瘍に対して効果を示します。エストロゲンやプロゲステロンの影響を受ける腫瘍に対して、これらのホルモンの作用を抑える薬剤を使用することで、がんの進行を防ぎます。例えば、タモキシフェンやアナストロゾールなどがこの治療に用いられます。ホルモン療法は、特に閉経後の女性に対して有効とされ、治療期間中の副作用は比較的軽度であることが特徴です。

標的療法は、特定の分子や経路を標的にすることで、がん細胞の増殖を抑える新たなアプローチです。卵巣がんに関連する遺伝子変異や特定のタンパク質に着目した治療薬が開発されており、例えば、バルバシチニブやオラパリブといったPARP阻害剤が挙げられます。PARP阻害剤は、DNA修復に関与する酵素を阻害することで、がん細胞の死滅を促進します。これらの薬剤は、特にBRCA遺伝子に変異を持つ患者に対して高い有効性を示します。

免疫療法は、患者自身の免疫系を活性化させることによってがんを攻撃させる方法です。このアプローチは比較的新しく、卵巣がん治療においても研究が進められています。免疫チェックポイント阻害剤などの薬剤が注目されており、特に進行した卵巣がんの患者に対して新たな治療の選択肢を提供しています。

卵巣がん治療薬の開発には、さまざまな関連技術が用いられています。分子生物学や遺伝子工学の進歩により、がん細胞の特性やその生物学的なメカニズムについての理解が深まり、新たな標的となる分子の発見が進んでいます。また、臨床試験を通じた新薬の評価も重要であり、新たな治療法の承認を促進するためには、これらの研究が欠かせません。

さらに、個別化医療の概念も治療薬の開発において重要となっています。患者の遺伝的背景や腫瘍の特性に基づいて、最適な治療法を選択することで、治療効果を最大限に引き出すことを目指すアプローチです。このため、バイオマーカーの発見や、それに基づく治療法の最適化が求められています。

卵巣がん治療薬は、現代の医学における重要な進展を示し、患者一人一人に適した治療法の選択を可能にするものです。これにより、治療の成功率と患者の生活の質を大きく向上させることが期待されており、さらなる研究と開発が進められることが望まれています。将来的には、多くの患者がより良い治療を受け、卵巣がんからの回復を果たすことができるようになることが期待されています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 卵巣がん治療薬の世界市場見通し2023年-2029年(Ovarian Cancer Drugs Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

卵巣がん治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp